Welcome to our dedicated page for Immuron SEC filings (Ticker: IMRN), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Immuron Limited’s SEC filings document its foreign private issuer disclosures and ASX announcements furnished on Form 6-K. The filings include half-year financial reports, strategic updates and investor presentations describing the company’s oral polyclonal antibody platform, Hyper-Immune products, Travelan®, ProIBS®, and clinical programs for gastrointestinal infectious diseases.
The filing record also covers shareholder meeting results, small-holding share sale facility disclosures, R&D Tax Incentive notices, regional sales updates, and governance authorizations by the board. These documents provide formal disclosures on operating results, research and development funding, ordinary-share matters, and public-company reporting obligations for IMRN’s ASX and Nasdaq-traded securities.
Immuron Limited provides an update via an investor presentation highlighting strong growth in its over-the-counter products and progress in its R&D pipeline. For FY 2025, global sales revenue reached $7.3m, up 49%, with Australian sales of $5.3m up 40% and North American sales of $2.0m up 76%. Gross profit margin was 65.4%, and EBITDA excluding R&D was a loss of $3.1m, a $2.1m improvement.
The company reports continued Travelan sales growth, with FY 2026 first-half global net sales of AUD$4.2m, up 5% year-on-year, driven mainly by Australia. Immuron notes FDA approval of the -529 IND for recurrent C. difficile infection and statistically significant Phase 2 results for Travelan, alongside updated peak U.S. sales expectations for -529 of US$400m from a consultancy. The outlook for FY 2026 includes continued year-on-year sales growth, progress toward EBITDA breakeven (excluding R&D), preclinical data for -986 in VRE, an end-of-Phase 2 meeting with the FDA for Travelan, and initiation of a Phase 2 trial for -529 in the first half of 2026.
Immuron Limited reports unaudited first-half global sales of Travelan® of AUD$4.2 million, up 5% on the prior comparative period. Second-quarter sales were AUD$2.2 million, 11% higher than the prior quarter, reflecting continued momentum.
In Australia, H1 sales reached AUD$3.3 million, up 13% on the prior period, with Q2 at AUD$1.7 million, also up 11%. Growth was driven by digital and social media marketing, stronger in‑store promotion, new store rollouts, and increased South East Asian travel, partially offset by a one‑off stock reduction by a major pharmacy group. Immuron also launched its new product ProIBS® into the Australian market.
In the U.S., H1 sales were AUD$0.9 million, up 17% on the prior period, aided by Amazon store improvements and expanded social media marketing. In Canada, H1 sales were AUD$56 thousand, down 85% on the prior period due to prior pipeline fill, but Q2 sales of AUD$42 thousand rose 191% on the prior quarter, with further distribution planned, including a Travelan® launch into Jean Coutu pharmacies in 3QFY26.
Immuron Limited furnished a Form 6-K highlighting that its Chief Executive Officer, Steven Lydeamore, will present virtually at the Emerging Growth Conference on Thursday, January 22, 2026, from 2:40 pm to 2:50 pm U.S. Eastern Time. The filing provides a registration link for live attendance and notes that an archived webcast will be available after the event.
The content also describes Immuron as an Australian biopharmaceutical company focused on orally delivered targeted polyclonal antibodies for infectious diseases. It outlines key products and programs including Travelan for travelers’ diarrhea, IMM-529 for recurrent Clostridioides difficile infection, and the distributed product ProIBS for irritable bowel syndrome symptoms.
Immuron Limited has called an Extraordinary General Meeting for 12 February 2026 to seek shareholder approval to ratify prior share issues made under its at-the-market (ATM) funding facility. Shareholders are being asked to approve two resolutions ratifying the issue of 28,278,923 shares under ASX Listing Rule 7.1 and 26,821,997 shares under Listing Rule 7.1A, for a total of 55,100,920 fully paid ordinary shares. The shares were issued in several ATM drawdowns in October, November and December 2025 at prices between $0.07560 and $0.08860 per share.
The company previously filed a Form F-3 and ATM prospectus in the United States allowing it to raise up to US$15 million over three years, and later extended the ATM facility by an additional approximate aggregate offering price of US$2,847,954. Funds raised are intended to support working capital and various projects. The board unanimously recommends that shareholders vote in favour of both ratification resolutions.
Immuron Limited furnished a Form 6-K to provide U.S. investors with copies of two announcements it filed with the Australian Securities Exchange. The announcements, dated December 16, 2025, are an Application for quotation of securities and a related Cleansing Notice, both attached as exhibits to the report.
Immuron Limited submitted a Form 6-K as a foreign private issuer for December 2025. The company is furnishing to U.S. investors two announcements it released to the Australian Securities Exchange on December 15, 2025, including an application for quotation of securities and a cleansing notice.
The materials are provided as exhibits to the Form 6-K and are expressly stated not to be treated as filed for Exchange Act purposes or automatically incorporated into other U.S. securities filings unless specifically referenced.
Immuron Limited submitted a report as a foreign private issuer to share information it had already released on the Australian Securities Exchange. The report attaches two December 11, 2025 ASX announcements: an application for quotation of securities and a cleansing notice. These documents are furnished to U.S. regulators for information purposes and are not automatically incorporated into other U.S. securities law filings unless specifically referenced later.
Immuron Limited submitted a Form 6-K as a foreign private issuer, mainly to furnish an announcement it released to the Australian Securities Exchange. The attached exhibit, titled “Uniformed Services University to Release Topline Data,” is included as Exhibit 99.1.
The company clarifies that this Form 6-K, including the exhibit, is being furnished rather than filed under U.S. securities laws and will not be incorporated into other U.S. securities filings unless specifically referenced.
Immuron Limited submitted a Form 6-K as a foreign private issuer for December 2025 to furnish an announcement made to the Australian Securities Exchange. The filing explains that the company published a public notice on December 4, 2025 titled “Change of Share Registry,” which is attached as Exhibit 99.1. The Form 6-K specifies that this information is being furnished, not filed, under U.S. securities laws and will not be incorporated into other securities law filings unless specifically referenced.